Welcome to our dedicated page for Corbus Pharmaceuticals Holdings news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceuticals Holdings stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage drug development company dedicated to creating innovative therapies for rare, chronic, and serious inflammatory and fibrotic diseases. The company's leading product candidate, Resunab™, is a pioneering oral anti-inflammatory drug designed to resolve inflammation through an endogenous pathway. Resunab™ is set to begin three Phase 2 clinical trials in 2015 targeting cystic fibrosis, diffuse systemic sclerosis (scleroderma), and dermatomyositis, all conditions where inflammation significantly contributes to disease progression. Additionally, Resunab™ has the potential to address other rare inflammatory diseases.
Corbus Pharmaceuticals is also a precision oncology company with a diversified portfolio aimed at tackling serious illnesses using scientific approaches to well-known biological pathways. The company's development pipeline includes several key candidates:
- CRB-701: A next-generation antibody-drug conjugate (ADC) targeting Nectin-4 on cancer cells, releasing a cytotoxic payload.
- CRB-601: An anti-integrin monoclonal antibody blocking TGFβ activation expressed on cancer cells.
- CRB-913: A second-generation, peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Recent developments include the FDA clearance of CRB-601 for a Phase 1 study expected to enroll the first patient in the summer of 2024. Additionally, the company completed a public offering in February 2024, raising $94.5 million, and reported $127 million in cash, cash equivalents, and investments as of February 2, 2024, extending their cash runway through March 31, 2027.
Corbus aims to use the net proceeds from their recent underwritten offering to further their clinical development pipeline, ensuring robust progress across their range of innovative therapies. The company's partnerships and collaborations, such as with CSPC Pharmaceutical Group, highlight their commitment to advancing their pipeline and translating scientific discoveries into effective treatments for patients worldwide.
Headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals is at the forefront of the biotechnology field, continuously striving to bring first-in-class treatments to market, thereby addressing unmet medical needs and improving patient outcomes. For more information, visit corbuspharma.com.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported its Q1 2021 financial results, highlighting a revenue drop to approximately $648,000 from $1.8 million in Q1 2020. Operating expenses decreased by $15.5 million to about $16.1 million, primarily due to reduced clinical trial and manufacturing costs. The net loss narrowed to approximately $16.1 million or $0.14 per share, down from $29.7 million or $0.43 per share a year earlier. The company maintains a strong financial position with $125 million in cash, expected to support operations into Q1 2024. Topline data for the Phase 3 study of lenabasum in dermatomyositis is anticipated in Q2 2021.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present at three upcoming virtual investor conferences. The events include the RBC Capital Markets Global Healthcare Conference on May 18, Oppenheimer Rare & Orphan Disease Summit on May 21, and the Jefferies Virtual Global Healthcare Conference on June 1. Each presentation will feature a fireside chat followed by a Q&A session. An audio webcast will be available on their website, with replays lasting 90 days. Corbus focuses on developing medicines that target the endocannabinoid system, with its lead candidate being lenabasum.
Corbus Pharmaceuticals Holdings announced the enrollment of the last participant in a Phase 2 study of lenabasum for treating systemic lupus erythematosus (SLE). This exploratory trial involves 101 participants and evaluates lenabasum's safety and efficacy alongside standard treatments over 16 weeks. The study is the first to target the cannabinoid receptor type 2 in SLE, with primary results expected in the second half of 2021. Lenabasum aims to provide an alternative to immunosuppressive treatments for inflammatory diseases.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the completion of the final visit in the double-blind part of its Phase 3 DETERMINE study of lenabasum for treating dermatomyositis, a rare autoimmune disease. Topline data is expected in Q2 2021. The trial, involving 176 subjects, evaluates lenabasum's safety and efficacy against standard treatments. Lenabasum, granted Orphan Drug Designation by the FDA and EMA, aims to offer a safer alternative to current options. Dermatomyositis affects approximately 80,000 patients in North America, Europe, and Japan.
Corbus Pharmaceuticals (CRBP) announced progress in its clinical studies and a robust financial position with $127M cash on hand, expected to sustain operations into 2024. The Phase 3 DETERMINE study of lenabasum for dermatomyositis is on track for topline data in Q2 2021. While lenabasum did not meet primary endpoints in previous studies for systemic sclerosis and cystic fibrosis, the company is focusing on new drug development targeting metabolic diseases and cancer, with clinical studies anticipated in 2022.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present at two virtual investor conferences. The 33rd Annual Virtual Roth Conference is scheduled for March 16, 2021 at 1:30 PM EST, followed by the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021 at 1:10 PM EST. Both events will include a fireside chat and Q&A session. Investors can access audio webcasts and replays on the Corbus website. Corbus develops innovative medicines targeting the endocannabinoid system, with its lead candidate, lenabasum, in trials for inflammatory diseases.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) will report its fourth quarter and year-end financial results on March 15, 2021, at 8:30 a.m. ET. The conference call will be led by CEO Yuval Cohen and will include the management team. Investors can join by dialing (877) 407-3978 for domestic or (412) 902-0039 for international access. A live webcast will also be available.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced its participation in a webinar hosted by the New York Academy of Sciences on January 27, 2021. The event will feature presentations detailing the company's pipeline, including mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from its oncology and metabolism programs. Key topics will include new insights into acute inflammation and the therapeutic potential of cannabinoid receptors. The presentations will be made by experts from the company and academia.
Corbus Pharmaceuticals announced that CEO Yuval Cohen will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 12:35 PM EST. This event will be accessible through a live audio webcast. Corbus is known for developing lenabasum, a treatment targeting the endocannabinoid system for chronic inflammatory diseases.
Corbus Pharmaceuticals (CRBP) announced plans to shorten its Phase 3 dermatomyositis trial from 52 to 28 weeks, projecting topline data by Q2 2021. This strategic move follows recent competitive pressures and extends the company's cash runway into Q2 2022. Financial results showed a net loss of $34.9 million for Q3 2020, up from $20.8 million year-over-year, with revenue decreasing to $1.2 million. Despite setbacks in the RESOLVE-1 systemic sclerosis and cystic fibrosis studies, Corbus remains committed to advancing its pipeline, including ongoing clinical trials for systemic lupus erythematosus.
FAQ
What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?
What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?
What diseases does Corbus Pharmaceuticals target?
What is Resunab™?
What are the key products in Corbus’ development pipeline?
Where is Corbus Pharmaceuticals headquartered?
What recent financial developments has Corbus Pharmaceuticals announced?
Who are Corbus Pharmaceuticals’ partners?
When is Corbus Pharmaceuticals expected to begin the Phase 1 study of CRB-601?
What is the focus of CRB-701?
What is the purpose of the recent underwritten offering by Corbus Pharmaceuticals?
How can potential investors learn more about Corbus Pharmaceuticals' offerings?
